Final Program

TUESDAY • MAY 17 329
1006 Subclinical Albuminuria as a Prognostic Indicator in Group 1
Pulmonary Arterial Hypertension/N.P. Nickel, J.P. Fessel, A.R.
Hemnes, J. Rand, L. Wheeler, J. Loyd, E.D. Austin, Nashville, TN,
p.A6309
1007 Perioperative Morbidity and Mortality in Patients with
Pulmonary Hypertension Undergoing Non-Cardiac Surgery: An
Analysis of Admission Records from the Nationwide Inpatient
Sample from 2005-2009/K. Dudley, R. Lobato, J. Wong, B.
Maxwell, K. Rhoads, R.T. Zamanian, Stanford, CA, p.A6310
1008 Identification of Plasma Biomarkers Associated with the
Development of Scleroderma-Associated Pulmonary Arterial
Hypertension/D. Fox, C. Meadows, C. Abbott, R. Kumar, J.C.
Robinson, J.W. Anderson, A. Fischer, K.R. Stenmark, B.B.
Graham, T.M. Bull, Aurora, CO, p.A6311
1009 A Randomized Clinical Trial of Anastrozole in Pulmonary
Arterial Hypertension/S.M. Kawut, C. Archer-Chicko, A.
DeMichele, D. Dubow, J. Fritz, B. Ky, H. Palevsky, A. Palmisciano,
M. Patel, D. Pinder, K. Propert, K.A. Smith, F. Stanczyk, A. Vaidya,
C.E. Ventetuolo, Philadelphia, PA, p.A6312
1010 Borderline Pulmonary Pressure Is Associated with Worse
Survival in Patients at Risk for Pulmonary Hypertension - A
Retrospective Single Center Analysis/P. Douschan, G. Kovacs,
V. Foris, A. Avian, A. Olschewski, H. Olschewski, Graz, Austria,
p.A6313
1011 Characterization of Cardiopulmonary Exercise Testing
Parameters in Patients with Borderline Pulmonary Arterial
Pressure/R. Jiang, H. Liu, L. Wang, Q.-H. Zhao, S.-G. Gong, J. He,
J.-M. Liu, Z.-C. Jing, Shanghai, China, p.A6314
1012 The RESPITE Study: Riociguat in Patients with PAH and an
Inadequate Response to Phosphodiesterase 5 Inhibitors/M.M.
Hoeper, P.A. Corris, J. Klinger, D. Langleben, R. Naeije, G.
Simonneau, R.L. Benza, Hannover, Germany, p.A6315
1013 Predicting Outcomes in Pulmonary Arterial Hypertension
Based on Estimated Glomerular Filtration Rate/M.M. Chakinala,
D.W. Coyne, R.L. Benza, A.E. Frost, M.D. McGoon, B.K. Hartline,
R.P. Frantz, M. Selej, D.R. Mink, H.W. Farber, St. Louis, MO,
p.A6316
1014 Initial Combination with Bosentan and Sildenafil as Compared
with Initial Monotherapy with the Same Drugs in Patients with
Pulmonary Arterial Hypertension: A Case-Control, Multicenter
Study/M. Palazzini, N. Hirani, F. Dardi, J. Weatherald, C. Bachetti,
M.V. Thakrar, G. Mazzanti, D. Helmersen, A. Manes, E. Gotti, A.
Rinaldi, A. Albini, E. Monti, S. Fukui, D. Guarino, N. Galie, Bologna,
Italy, p.A6317
1015 Comparative Outcome of Incident Patients with Pulmonary
Hypertension Due to Left Heart Disease According with the
Haemodynamic Classification of the 2015 ESC-ERS Pulmonary
Hypertension Guidelines/A. Rinaldi, M. Palazzini, C. Bachetti, E.
Gotti, G. Mazzanti, F. Dardi, A. Albini, E. Monti, S. Fukui, D.
Guarino, N. Galie, A. Manes, Bologna, Italy, p.A6318
1016 Genomics and Survival in PAH: Results of a GWAS/R.L. Benza,
M. Gomberg-Maitland, H. Wiener, A. Frost, D. Langleban, T. Pulido,
A. Torbicki, P. Correa-Jaque, T. Demarco, M. Tamari, T. Hirota, M.
Kubo, M. Passineau, H.K. Tiwari, Pittsburgh, PA, p.A6319
1017 EIF2AK4 Mutation-Carriers with PVOD Present Distinct
Features Within the Remodeled Lung Vasculature/E. Nossent,
D. Montani, B. Girerd, F. Perros, F. Soubrier, E. Fadel, K.
Grunberg, H.J. Bogaard, G. Simonneau, A. Vonk Noordegraaf,
M.J.C. Humbert, P. Dorfmuller, Amsterdam, Netherlands, p.A6320
1018 Pulmonary Arterial Capacitance Predicts Survival in
Pulmonary Arterial Hypertension/N. Al-Naamani, S. Muthukuru,
N.S. Hill, I.R. Preston, K.E. Roberts, Boston, MA, p.A6321
C107
POSTER DISCUSSION SESSION
IMMUNITY, EXACERBATION AND IMMUNE CELL
FUNCTION IN COPD
2:15 p.m. - 4:15 p.m. MOSCONE CENTER
Room 2014 (West Building, Level 2)
Poster Viewing 2:15-3:00
Discussion 3:00-4:15
501 Defective Phagocytosis of Aspergillus Fumigatus by COPD
Macrophages/K.B.R. Belchamber, A. Shah, P.J. Barnes, D.
Armstrong-James, L. Donnelly, London, United Kingdom, p.A6322
502 Airway Glucose in Virus-Induced COPD Exacerbations/R.
Hewitt, J. Webber, H. Farne, M.-B. Trujillo-Torralbo, J. Footitt, P.L.
Molyneaux, S.L. Johnston, J. Tregoning, P. Mallia, London, United
Kingdom, p.A6323
503 Toll-Like Receptor 9, a Key to Attenuation of Disease
Progression in a Mouse Model of Chronic Obstructive
Pulmonary Disease/T. Sato, K. Nakashima, Y. Shibata, R. Ushio,
M. Ikeda, H. Watanabe, K. Nagai, K. Tashiro, H. Nagakura, N.
Horita, M. Yamamoto, M. Shinkai, M. Kudo, D. Klinman, T. Kaneko,
Yokohama, Japan, p.A6324
504 Combination Effect of p38 MAPK Inhibition and Corticosteroid
on Haemophilus Influenzae Stimulated Alveolar Macrophages
from COPD Patients/S. Lea, R. Khalaf, H. Metcalfe, D. Singh,
Manchester, United Kingdom, p.A6325
505 Lung Eosinophils and GATA3+ Cells Accumulate in Draining
Lymph Nodes in Chronic Obstructive Pulmonary Disease/P.
Jogdand-Sathe, M. Mori, A. Walls, T. Mauad, C. Sanden, J.S.
Erjefalt, Lund, Sweden, p.A6326
506 Identification and Functional Characterization of Novel
Dendritic Cell Subsets in Chronic Obstructive Pulmonary
Disease (COPD) Lung/T. Naessens, Y. Morias, B. Lambrecht, D.
Cunoosamy, Molndal, Sweden, p.A6327
507 Differences in Neutrophil Chemotactic Responses in COPD
and Health, in the Stable State and During Exacerbations/G.M.
Walton, A. Culliford, H. Greenwood, J. Patel, A.J.A. McGuinness,
R.A. Stockley, E. Sapey, Birmingham, United Kingdom, p.A6328
508 Regulation of IL-22-Producing Human Lung Natural Killer Cells
by the Dendritic Cell Inhibitory Receptor, IL-22 Binding
Protein, Is Decreased in COPD/C. Peng, V.R. Stolberg, B.L.
Saxton, J.P. Brown, L. McCloskey, J.L. Curtis, C.M. Freeman,
Guiyang, China, p.A6329
TUESDAY AFTERNOON
ATS 2016 • San Francisco